Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
Crossref DOI link: https://doi.org/10.1007/s10549-014-3015-6
Published Online: 2014-06-13
Published Print: 2014-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Clemons, Mark J.
Cochrane, Brandy
Pond, Gregory R.
Califaretti, Nadia
Chia, Stephen K. L.
Dent, Rebecca Alexandra
Song, Xinni
Robidoux, Andre
Parpia, Sameer
Warr, David
Rayson, Daniel
Pritchard, Kathleen I.
Levine, Mark N.
Text and Data Mining valid from 2014-06-13